Acquired Angioedema Type 2 C5680381
A form of angioedema where autoantibodies interfere with C1 inhibitor function. It causes recurrent swelling episodes similar to other types. Management involves immunosuppressants and medications to control swelling attacks.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Recurrent angioedema
Throat tightness
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Skin swelling
(immunologic)Urticaria absence
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
C1 Esterase Inhibitor Concentrate
Purified C1-INH replacement therapy effective for both acute attacks and long-term prophylaxis by restoring functional C1 inhibitor levels.
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Icatibant
Bradykinin receptor antagonist providing effective acute attack management by blocking the downstream effects of excess bradykinin.
Additional treatment options
Ecallantide
Kallikrein inhibitor offering an alternative mechanism for acute attack control when C1-INH products or icatibant are contraindicated.
medicationTrigger Identification and Management
Systematic avoidance of medications and environmental factors known to precipitate attacks such as ACE inhibitors and trauma.
lifestyleDisease Activity Surveillance
Regular assessment of attack frequency, severity, and functional impact combined with laboratory monitoring of C1-INH function and complement levels.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acquired Angioedema Type 2 C5680381?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bygum A, Fagerberg CR, Vestergaard H, et al. Acquired Angioedema and C1-Inhibitor Autoantibodies: Clinical Features and Associated Conditions. J Clin Immunol. 2021.
Maurer M, Magerl M, Ansotegui I, et al. The International WAO/EAACI Guideline for the Management of Hereditary and Acquired Angioedema. Allergy. 2022.
Zanichelli A, Azin GM, Suffritti C, et al. Rituximab in Acquired Angioedema with Anti-C1 Inhibitor Autoantibodies: A Prospective Open-Label Study. J Invest Dermatol. 2020.
Caballero T, Mares J, Pedregosa L, et al. Treatment Outcomes in Acquired Angioedema: A Systematic Review and Meta-Analysis. Ann Allergy Asthma Immunol. 2023.
Medication Comparisons
Compare medications used to treat Acquired Angioedema Type 2 C5680381. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy